Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

About this update from Aurinia Pharmaceuticals Inc

ROCKVILLE, Md. & EDMONTON, Alberta --(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City , September 9-11, 2024 . Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 10 , at 10:30 AM EST . This session will not include a webcast. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021 , the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta , and its U.S. commercial office is in Rockville, Maryland . The Company focuses its development efforts globally. View source version on businesswire.com : https://www.businesswire.com/news/home/20240828651786/en/ Media & Investor Inquiries: Andrea Christopher , Corporate Communications & Investor Relations , Aurinia [email protected] General Investor Inquiries: [email protected] Source: Aurinia Pharmaceuticals Inc.

View stock analysis, news, and events for Aurinia Pharmaceuticals Inc